Managing rheumatoid arthritis (RA) can be exhausting in itself. You’re likely juggling medications, doctor appointments, and various lifestyle changes. Since the condition affects people differently and can change from month to month, it’s important to keep track of your symptoms and how you respond to treatments. Having good records can be helpful for your healthcare team.

cliexa-RA has been featured as one of the Best Rheumatoid Arthritis Apps of 2018!

//www.healthline.com/health/best-ra-apps

 

cliexa® partners with the University of Colorado Boulder’s Cognitive and Affective Neuroscience Lab (CANLab) for Multidimensional Pain Tracking and Predictive Analytics Research.
cliexa® Partners with Institute of Cognitive Science at University of Colorado Boulder

Denver, CO, February 28, 2018 — cliexa, Inc., which offers a suite of mobile platforms for chronic disease management, announces its collaboration with CU Boulder’s CANLab and Institute of Cognitive Science (ICS). cliexa will collaborate with CANLab’s team, headed by Tor Wager, a professor of psychology and neuroscience, as they lead in multidimensional pain tracking and predictive analytics research.

CU Boulder jointly filed a provisional patent with cliexa for the multidimensional objective pain concept with CANLab. CANLab focuses on identifying a particular pattern of brain activity, which is diagnostic of physical pain. cliexa-Ease’s mobile platform hosts the research concept and is being used to further develop CANLab’s existing pain studies. cliexa-Ease will deliver an exclusive pain assessment model which, in collaboration with CU Boulder, anticipates commercialization by mid 2018.

Mehmet Kazgan, founder and CEO of cliexa, explains how they are excited about the partnership with Wager’s CANLab because of its “leading research studies for multidimensional pain tracking.” “Working with neuroscientists at CU Boulder is taking the cliexa platform to the next level of objectifying patient outputs with multiple reference points.”

Wager highlights how the collaboration will “expand our ability to understand how emotion affects pain in daily life.” Pavel Goldstein, the scientific lead of the project, adds that the partnership will provide both “an incredible opportunity to establish a platform for researching chronic pain conditions” and “important feedback to pain patients and their clinicians with unique information about patient health.”

About The Cognitive and Affective Neuroscience Lab

Professor Tor Wager leads CANLab, which is housed in CU Boulder’s Institute of Cognitive Science (ICS) and the Psychology and Neuroscience Department. CANLab uses machine-learning to develop fMRI-based biomarkers for clinically relevant outcomes, such as pain. It subsequently tests how psychological factors influence these biomarkers. The lab also engages in collaborative, translational research, which incorporates brain systems-level analyses into the study of clinical disorders, including PTSD, depression, schizophrenia, and chronic pain.

Learn more about CAN Lab at //canlabweb.colorado.edu

About cliexa
The mobile platform technology developed by cliexa enables patients to track their chronic disease activity by quantifying symptoms using scientifically-proven and clinically-validated scoring models. cliexa delivers quantified disease activity and medication adherence through patient reported outcomes through real-time integration to electronic medical records, which streamline processes and increase efficiency in population health management.

Learn more about cliexa at //www.cliexa.com

See the Press release here:

Top 50 Startups to Watch in CO

cliexa is listed as one of the 50 Startups featured in Built in Colorado‘s article:

//www.builtincolorado.com/2018/01/16/50-colorado-tech-startups-watch-2018

Venture Hall accelerator program today announced cliexa (www.cliexa.com) to receive a zero-equity investment of $25,000, as awarded by their peers.

Also announced at Maine Startup Insider website, cliexa won the 1st place award.

Developed in partnership with Village Capital, an international accelerator and venture capital firm, Venture Hall’s program includes an intense peer-review process that has been shown to forecast success better than investors.

“We are honored and feel extremely lucky to be part of Venture Hall Accelerator Program this summer as cliexa. It was not just an accelerator program with just mentor and training sessions, but also working sessions with industry experts and clinicians directly from Maine Health and Unum,”said Mehmet Kazgan, CEO and co-founder of cliexa,” Venture Hall’s program played an amazing catalyzer role by working on specific areas for each startup and reached out to exactly the right group of resources from mentors pool. We came with a list of goals to Portland, Maine and Venture Hall made those happen. cliexa would love to be part of Maine’s economic growth.”

The six startup teams to complete the accelerator were selected from a competitive applicant pool of over 90 companies from 27 states and 12 countries. The accelerator program was delivered in partnership with MaineHealth and Unum to bring more world-class startup talent to Maine, and to provide a way for employees of both partner organizations to assist in the development of innovative new solutions to challenging problems.